Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

Authors
Publication date
1 January 2011
Publisher
Doi
    View on PubMed

    Abstract

    The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of the anti-EGFR antibody cetuximab, in persistent or recurrent carcinoma of the cervix

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Carolina Digital Repository

      redirect
      oaicdr.lib.unc.edu:n870zz50r
      Last time updated on 24/11/2020